ES2186714T3 - Uso de sustipo simple alpha 8 en la preparacion de medicamentos para el tratamiento de infecciones virales del higado. - Google Patents

Uso de sustipo simple alpha 8 en la preparacion de medicamentos para el tratamiento de infecciones virales del higado.

Info

Publication number
ES2186714T3
ES2186714T3 ES95910629T ES95910629T ES2186714T3 ES 2186714 T3 ES2186714 T3 ES 2186714T3 ES 95910629 T ES95910629 T ES 95910629T ES 95910629 T ES95910629 T ES 95910629T ES 2186714 T3 ES2186714 T3 ES 2186714T3
Authority
ES
Spain
Prior art keywords
treatment
viral
ifn
liver
medicines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95910629T
Other languages
English (en)
Inventor
Graham Russell Foster
Howard Christopher Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imperial College of London
Original Assignee
Imperial College of London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9404379A external-priority patent/GB9404379D0/en
Priority claimed from GB9420340A external-priority patent/GB9420340D0/en
Application filed by Imperial College of London filed Critical Imperial College of London
Application granted granted Critical
Publication of ES2186714T3 publication Critical patent/ES2186714T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE HA COMPROBADO QUE SUBTIPOS INDIVIDUALES DE INTERFERONA-{AL} (IFN-{AL}) POSEEN DISTINTA ACTIVIDAD ANTI-VIRAL EN DISTINTOS TIPOS DE CELULAS Y SON POR TANTO UTILIZADOS PARA PREVENIR O TRATAR LAS INFECCIONES VIRALES EN TIPOS DE CELULAS EN LOS CUALES SE ENCUENTRAN MAS ACTIVAS. EL SUBTIPO INDIVIDUAL DE ELECCION TIENE UNA ACTIVIDAD ANTI-VIRAL RELATIVAMENTE BAJA EN OTROS TIPOS DE CELULAS PARA REDUCIR EL RIESGO DE EFECTOS SECUNDARIOS. SE PREFIEREN LA IFN-{AL}{SUB,10} Y LA IFN-{AL}{SUB,17} PARA SU USO EN EL TRATAMIENTO DE LAS INFECCIONES DE PULMON VIRALES, Y LA IFN{AL}{SUB,8} PARA SU USO EN EL TRATAMIENTO DE LAS INFECCIONES DE HIGADO VIRALES.
ES95910629T 1994-03-07 1995-03-07 Uso de sustipo simple alpha 8 en la preparacion de medicamentos para el tratamiento de infecciones virales del higado. Expired - Lifetime ES2186714T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9404379A GB9404379D0 (en) 1994-03-07 1994-03-07 Therapeutic improvement
GB9420340A GB9420340D0 (en) 1994-10-10 1994-10-10 Therapeutic improvement

Publications (1)

Publication Number Publication Date
ES2186714T3 true ES2186714T3 (es) 2003-05-16

Family

ID=26304449

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95910629T Expired - Lifetime ES2186714T3 (es) 1994-03-07 1995-03-07 Uso de sustipo simple alpha 8 en la preparacion de medicamentos para el tratamiento de infecciones virales del higado.

Country Status (10)

Country Link
US (1) US6007805A (es)
EP (1) EP0741577B1 (es)
JP (1) JP4001379B2 (es)
AT (1) ATE227133T1 (es)
AU (1) AU1854695A (es)
DE (1) DE69528751T2 (es)
DK (1) DK0741577T3 (es)
ES (1) ES2186714T3 (es)
PT (1) PT741577E (es)
WO (1) WO1995024212A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0563487A1 (en) * 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
GB9702021D0 (en) * 1997-01-31 1997-03-19 Imperial College Medicaments
US6436391B1 (en) * 1997-01-31 2002-08-20 Imperial College Of Science, Technology & Medicine Use of interferon (IFN)-α8 and -α14 as vaccine adjuvants
IT1295657B1 (it) * 1997-11-04 1999-05-24 Alfa Wassermann Spa Oligopeptidi antiparalleli e oligopeptidi idrofobicamente complementari, matrici che li contengono e loro uso nella
ES2138565B1 (es) * 1998-05-13 2000-08-16 Inst Cientifico Tecnol Navarra Uso del interferon alfa 5 en el tratamiento de las hepatopatias viral es.
GB9818445D0 (en) * 1998-08-24 1998-10-21 Imp College Innovations Ltd Medicaments
AU2587002A (en) * 2000-11-03 2002-05-15 Biomedicines Inc Method for short-term and long-term drug dosimetry
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
IL161889A0 (en) * 2001-11-09 2005-11-20 Biomedicines Inc Method for treating diseases with omega interferon
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
JP4866612B2 (ja) * 2003-11-12 2012-02-01 株式会社林原生物化学研究所 生理活性複合体
NZ547157A (en) 2003-12-10 2009-07-31 Medarex Inc Interferon Alpha Antibodies and their uses
EP2327724A3 (en) 2004-02-02 2011-07-27 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
AU2005245918A1 (en) 2004-05-19 2005-12-01 F. Hoffmann-La Roche Ag Interferon-alpha polypeptides and conjugates
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
MX2007014524A (es) 2005-05-18 2008-02-07 Maxygen Inc Polipeptidos desarrollados de interferon-alfa.
MX2008014870A (es) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
EP2049081B1 (en) 2006-08-09 2012-11-14 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
HRP20130259T1 (hr) 2007-04-23 2013-04-30 Intarcia Therapeutics, Inc. Suspenzijske formulacije inzulinotropnih peptida i njihove uporabe
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
KR20110005806A (ko) 2008-03-21 2011-01-19 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 인간 인터페론 α 서브타입 α8 및 그 변이 단백질을 특이적으로 인식하는 단일클론 항체
SMT201700583T1 (it) 2009-09-28 2018-01-11 Intarcia Therapeutics Inc Instaurazione e/o terminazione rapida di erogazione di farmaci in modo sostanzialmente stazionario
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
GB201215873D0 (en) 2012-09-05 2012-10-24 Alfacyte Ltd Compositions and methods relating to the treatment of allergy and allergic diseases
GB201404403D0 (en) * 2014-03-12 2014-04-23 Alfacyte Ltd Compositions and methods relating to the treatment of diseases
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
CA2998456A1 (en) 2015-09-15 2017-03-23 Alfacyte Ltd Compositions and methods relating to the treatment of diseases
RU2760007C2 (ru) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH657141A5 (de) * 1980-07-01 1986-08-15 Hoffmann La Roche Dns-sequenzen, rekombinante expressionsvektoren zur mikrobiellen herstellung von human-leukozyten-interferonen und transformierte mikroorganismen.
GB8303165D0 (en) * 1983-02-04 1983-03-09 Secher D S Monoclonal antibody
JPH02197539A (ja) * 1989-01-26 1990-08-06 Tanaka Kikinzoku Kogyo Kk 装飾品用Ｃｏ含有貴金属材料
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
DE69324671D1 (de) * 1992-02-10 1999-06-02 Interferon Sciences Inc Verbesserte alpha-interferon-zusammensetzung und verfahren zu ihrer herstellung aus leukocyten des menschlichen peripheren blute

Also Published As

Publication number Publication date
DE69528751T2 (de) 2003-07-10
DK0741577T3 (da) 2003-02-17
JP4001379B2 (ja) 2007-10-31
US6007805A (en) 1999-12-28
AU1854695A (en) 1995-09-25
EP0741577A1 (en) 1996-11-13
PT741577E (pt) 2003-03-31
DE69528751D1 (de) 2002-12-12
WO1995024212A1 (en) 1995-09-14
JPH09509955A (ja) 1997-10-07
ATE227133T1 (de) 2002-11-15
EP0741577B1 (en) 2002-11-06

Similar Documents

Publication Publication Date Title
ES2186714T3 (es) Uso de sustipo simple alpha 8 en la preparacion de medicamentos para el tratamiento de infecciones virales del higado.
ES2150496T3 (es) Cicloalquilimidazopiridinas condensadas.
YU7296A (sh) Farmaceutska kompozicija koja sadrži kombinaciju jedne protivvirusne supstance i jednog protivzapaljenskog glukokortikoida
FI20001231A7 (fi) 2-Deoksi-2,3-didehydro-N-asetyylineuramiinihapon johdannaisia ja niiden analogeja ja niiden käyttö antiviraalisina aineina
DE69230140D1 (de) Antivirale nucleosidkombination
ATE157251T1 (de) Verwendung von inositoltriphosphat zur behandlung von entzündungen
ES2125233T3 (es) Tratamiento de las infecciones retrovirales humanas con 2',3'-didesoxiinosina.
TR199903053T2 (xx) Benzimidazol t�revleri.
ES541103A0 (es) Procedimiento de obtencion de una composicion para el trata-miento de infecciones virales
ES2123323T3 (es) Asociacion de un compuesto con actividad antimicrobiana (por ejemplo lipoaminoacido n,n-octanoilglicina) y de un monoalquileter de glicerol y su uso como agente antimicrobiano.
ES2149276T3 (es) Imidazo(4,5-c)piridin-4-aminas.
MX9700538A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para las enfermedades cardiovasculares.
MX9308013A (es) 4-fenil-piridonas y 4-fenil-2-fenil-2-alcoxipiridinas sustituidas, procedimiento para su preparacion y medicamentos que los contienen.
CO5001019A1 (es) Composicion emulsionable para la represion de insectos, que se deriva del tipo de fenilpirazoles sustituidos en posi- cion 1, y no favorecen la formacion de cristales
ES2058343T3 (es) Piridinas disubstituidas.
TR199801289T2 (en) Terap�tik bile�ikler.
ES2129893T3 (es) Dinucleosido-5',5'-pirofosfatos.
ES2078462T3 (es) Esteres de castanoespermina anti-herpes.
ATE59778T1 (de) Verwendung von sulfonamidderivaten zur herstellung eines antivirusmittels.
ES2145114T3 (es) Combinacion de atovacuona con proguanil para el tratamiento de infecciones protozoarias.
IT1229223B (it) Composizioni veterinarie sinergisticamente attive e procedimento per la loro preparazione.
AR011586A1 (es) Agentes antivirales derivados del 6-bencil-1-etoximetil-5-uracilo sustituido y su uso para el tratamiento de infecciones virales
ES2087178T3 (es) Disulfato de ws7622a, procedimiento para su preparacion y su uso.
ES2103811T3 (es) Terapia antiviral.
MX9303985A (es) Nucleosidos terapeuticos.